Patents by Inventor Dae Seong Im
Dae Seong Im has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240053374Abstract: The invention relates to an adapter for mounting a conductive pipette, a sample tube opening/closing device, and an automatic sample analysis system and, more specifically, to an adapter for mounting a conductive pipette, a sample tube opening/closing device, and an automatic sample analysis system, in which dispensing of a liquid sample and extraction, amplification and testing of nucleic acids are integrally carried out. The sample tube opening/closing device includes: a housing that forms an inner space isolated from the outside and includes a door for carrying in/out a multi-well plate for biological samples, including a plurality of sample tubes in which biological samples are accommodated; and a sample tube opening/closing part that is installed in the inner space to be spaced apart from the multi-well plate for biological samples and automatically opens and closes the sample tubes.Type: ApplicationFiled: December 7, 2021Publication date: February 15, 2024Applicant: BIONEER CORPORATIONInventors: Han Oh PARK, Hanee PARK, Jong Kab KIM, Dae Seong IM, Eun Yeong KWON
-
Publication number: 20220106217Abstract: An apparatus for molding a window, the apparatus includes: a first molding part; a jig disposed below the first molding part, the jig including a bottom surface and a plurality of side surfaces configured to support and seat a work piece to be processed into a window; and an second molding part disposed on the bottom surface, wherein the second molding part includes: a lower surface adjacent to the bottom surface; an upper surface facing the lower surface; a first cavity having a first curved surface generally concave in a direction facing the lower surface; a plurality of second cavities extending from the first cavity, the plurality of second-cavities having second curved surfaces; and a plurality of movable molds disposed on the second-cavities supported for movement along the second curved surfaces, respectively.Type: ApplicationFiled: October 6, 2021Publication date: April 7, 2022Inventors: Seung KIM, Young Ki PARK, Byunghoon KANG, Seungho KIM, Oh Joo PARK, Jong Soo BAEK, Gyuin SHIM, Dae Seong IM
-
Publication number: 20210387891Abstract: The window molding apparatus for processing a member having first and second opposed, substantially flat sides and a bendable portion disposed therebetween, the apparatus includes a first molding part controlled to move in a substantially linear direction and a jig including a support surface on which the member is seated and a recess in the support surface to receive the bendable portion of the member and the first molding part.Type: ApplicationFiled: March 30, 2021Publication date: December 16, 2021Inventors: SEUNG KIM, Byunghoon Kang, Seungho Kim, Young Ki Park, Oh Joo Park, Jong Soo Baek, Gyuin Shim, Dae Seong Im
-
Publication number: 20210347827Abstract: The present invention provides a linear multimeric biomolecule polymer wherein a biomolecule is bonded to a polyubiquitin scaffold formed of two or more covalently bonded ubiquitins, by obtaining, from a host cell, a biomolecule bonded with a ubiquitin C-terminal tag through recombinant expression, and polyubiquitinating the biomolecule in vitro in the presence of proteins involved in ubiquitination, E1 (activation enzyme), E2 (conjugation enzyme), and E3 (ligase), and a substrate. The polymer according to the present invention may be used in the separation and purification of a biomolecule, the separation of a target material that binds to the biomolecule, etc.Type: ApplicationFiled: May 28, 2019Publication date: November 11, 2021Applicant: ONEGENE BIOTECHNOLOGY INC.Inventors: Sungjin Park, Dae Seong Im, Jaeyoung Choi
-
Patent number: 10744187Abstract: An insulin conjugate having improved in vivo duration and stability is provided. The conjugate is prepared by covalently linking insulin with an immunoglobulin Fc region via a non-peptidyl polymer, a long-acting formulation comprising the same, and a preparation method thereof. The insulin conjugate of the present invention maintains in vivo activity of the peptide at a relatively high level and remarkably increases the serum half-life thereof, thereby greatly improving drug compliance upon insulin treatment.Type: GrantFiled: April 27, 2018Date of Patent: August 18, 2020Assignee: HANMI SCIENCE CO., LTD.Inventors: Dae Hae Song, Jae Hee Shin, Young Jin Park, Dae Seong Im, Sung Min Bae, Se Chang Kwon
-
Publication number: 20180303907Abstract: An insulin conjugate having improved in vivo duration and stability is provided. The conjugate is prepared by covalently linking insulin with an immunoglobulin Fc region via a non-peptidyl polymer, a long-acting formulation comprising the same, and a preparation method thereof. The insulin conjugate of the present invention maintains in vivo activity of the peptide at a relatively high level and remarkably increases the serum half-life thereof, thereby greatly improving drug compliance upon insulin treatment.Type: ApplicationFiled: April 27, 2018Publication date: October 25, 2018Applicant: HANMI SCIENCE CO., LTD.Inventors: Dae Hae SONG, Jae Hee SHIN, Young Jin PARK, Dae Seong IM, Sung Min BAE, Se Chang KWON
-
Patent number: 9981017Abstract: An insulin conjugate having improved in vivo duration and stability is provided. The conjugate is prepared by covalently linking insulin with an immunoglobulin Fc region via a non-peptidyl polymer, a long-acting formulation comprising the same, and a preparation method thereof. The insulin conjugate of the present invention maintains in vivo activity of the peptide at a relatively high level and remarkably increases the serum half-life thereof, thereby greatly improving drug compliance upon insulin treatment.Type: GrantFiled: October 6, 2016Date of Patent: May 29, 2018Assignee: HANMI SCIENCE CO., LTD.Inventors: Dae Hae Song, Jae Hee Hee Shin, Young Jin Park, Dae Seong Im, Sung Min Bae, Se Chang Kwon
-
Patent number: 9669105Abstract: Disclosed is a liquid formulation in which a long-acting INF? conjugate that has improved in vivo duration and stability can be stored stably for a long period of time. It comprises a stabilizer comprising a buffer, a sugar alcohol, a non-ionic surfactant and an isotonic agent. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting INF? conjugates.Type: GrantFiled: October 26, 2011Date of Patent: June 6, 2017Assignee: HANMI SCIENCE CO., LTD.Inventors: Dae Seong Im, Jae Min Lee, Jong Soo Lee, Sung Min Bae, Se Chang Kwon
-
Publication number: 20170020991Abstract: An insulin conjugate having improved in vivo duration and stability is provided. The conjugate is prepared by covalently linking insulin with an immunoglobulin Fc region via a non-peptidyl polymer, a long-acting formulation comprising the same, and a preparation method thereof. The insulin conjugate of the present invention maintains in vivo activity of the peptide at a relatively high level and remarkably increases the serum half-life thereof, thereby greatly improving drug compliance upon insulin treatment.Type: ApplicationFiled: October 6, 2016Publication date: January 26, 2017Applicant: HANMI SCIENCE CO., LTDInventors: Dae Hae SONG, Jae Hee Hee SHIN, Young Jin PARK, Dae Seong IM, Sung Min BAE, Se Chang KWON
-
Patent number: 9492507Abstract: The present invention relates to an insulin conjugate having improved in vivo duration and stability, which is prepared by covalently linking insulin with an immunoglobulin Fc region via a non-peptidyl polymer, a long-acting formulation comprising the same, and a preparation method thereof. The insulin conjugate of the present invention maintains in vivo activity of the peptide at a relatively high level and remarkably increases the serum half-life thereof, thereby greatly improving drug compliance upon insulin treatment.Type: GrantFiled: April 4, 2011Date of Patent: November 15, 2016Assignee: HANMI SCIENCE CO., LTD.Inventors: Dae Hae Song, Jae Hee Shin, Young Jin Park, Dae Seong Im, Sung Min Bae, Se Chang Kwon
-
Patent number: 9061072Abstract: Disclosed is a liquid formulation of long-acting human growth hormone (hGH) conjugate, free of albumin, which can guarantee the stability of the long-acting hGH conjugate when stored over a long period of time, wherein the long-acting human growth hormone conjugate includes a human growth hormone linked to an immunoglobulin Fc region, and has a prolonged in vivo stability compared to the native form. The liquid formulation of hGH conjugate including a pH 5.0˜6.0 buffer, a sugar alcohol, a salt and a non-ionic surfactant is free of human serum albumin and other hazardous factors which are potentially contaminated with viruses, and can provide excellent storage stability customized for a long-acting hGH conjugate composed of an hGH polypeptide and an immunoglobulin Fc region which has higher molecular weight and in vivo durability, compared to the native.Type: GrantFiled: July 14, 2011Date of Patent: June 23, 2015Assignee: HANMI SCIENCE CO., LTDInventors: Sung Hee Hong, Byung Sun Lee, Dae Seong Im, Jae Min Lee, Sung Min Bae, Se Chang Kwon
-
Patent number: 8829163Abstract: Disclosed is a liquid formulation which allows long-acting EPO conjugates, that have improved in vivo duration and stability, to be stable when stored for a long period of time. It comprises a stabilizer composition characterized by buffer and mannitol. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting EPO conjugates.Type: GrantFiled: January 18, 2011Date of Patent: September 9, 2014Assignee: Hanmi Science Co., LtdInventors: Sung Min Bae, Dae Seong Im, Min Young Kim, Chang Ki Lim, Sung Youb Jung, Se Chang Kwon
-
Publication number: 20130287734Abstract: Disclosed is a liquid formulation in which a long-acting INF? conjugate that has improved in vivo duration and stability can be stored stably for a long period of time. It comprises a stabilizer comprising a buffer, a sugar alcohol, a non-ionic surfactant and an isotonic agent. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting INF? conjugates.Type: ApplicationFiled: October 26, 2011Publication date: October 31, 2013Applicant: HANMI SCIENCE CO., LTD.Inventors: Dae Seong Im, Jae Min Lee, Jong Soo Lee, Sung Min Bae, Se Chang Kwon
-
Publication number: 20130115231Abstract: Disclosed is a liquid formulation of long-acting human growth hormone (hGH) conjugate, free of albumin, which can guarantee the stability of the long-acting hGH conjugate when stored over a long period of time, wherein the long-acting human growth hormone conjugate includes a human growth hormone linked to an immunoglobulin Fc region, and has a prolonged in vivo stability compared to the native form. The liquid formulation of hGH conjugate including a pH 5.0˜6.0 buffer, a sugar alcohol, a salt and a non-ionic surfactant is free of human serum albumin and other hazardous factors which are potentially contaminated with viruses, and can provide excellent storage stability customized for a long-acting hGH conjugate composed of an hGH polypeptide and an immunoglobulin Fc region which has higher molecular weight and in vivo durability, compared to the native.Type: ApplicationFiled: July 14, 2011Publication date: May 9, 2013Applicant: HANMI SCIENCE CO., LTD.Inventors: Sung Hee Hong, Byung Sun Lee, Dae Seong Im, Jae Min Lee, Sung Min Bae, Se Chang Kwon
-
Publication number: 20130095090Abstract: Disclosed are a blood coagulation factor complex in which FacVIIa, a non-peptidyl polymer and an immunoglobulin Fc region are bonded by covalent bonds, and the uses thereof. The FacVIIa complex guarantees the in vivo activity of FacVIIa and significantly enhances the serum half life of FacVIIa, so that it is useful for developing long-acting FacVIIa formulations which can improve the compliance of role behavior of patients whose blood does not coagulate.Type: ApplicationFiled: June 30, 2011Publication date: April 18, 2013Applicant: HANMI SCIENCE CO., LTD.Inventors: Dae Hae Song, Sung In Lim, Chang Hwan Kim, Sung Kap Hong, Dae Seong Im, Se Chang Kwon
-
Publication number: 20130028918Abstract: The present invention relates to an insulin conjugate having improved in vivo duration and stability, which is prepared by covalently linking insulin with an immunoglobulin Fc region via a non-peptidyl polymer, a long-acting formulation comprising the same, and a preparation method thereof. The insulin conjugate of the present invention maintains in vivo activity of the peptide at a relatively high level and remarkably increases the serum half-life thereof, thereby greatly improving drug compliance upon insulin treatment.Type: ApplicationFiled: April 4, 2011Publication date: January 31, 2013Applicant: HANMI SCIENCE CO., LTD.Inventors: Dae Hae Song, Jae Hee Shin, Young Jin Park, Dae Seong Im, Sung Min Bae, Se Chang Kwon
-
Publication number: 20120296069Abstract: Disclosed is a liquid formulation which allows long-acting EPO conjugates, that have improved in vivo duration and stability, to be stable when stored for a long period of time. It comprises a stabilizer composition characterized by buffer and mannitol. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting EPO conjugates.Type: ApplicationFiled: January 18, 2011Publication date: November 22, 2012Applicant: HANMI SCIENCE CO., LTD.Inventors: Sung Min Bae, Dae Seong Im, Min Young Kim, Chang Ki Lim, Sung Youb Jung, Se Chang Kwon